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Abstract
Cyclic nucleotide phosphodiesterase-8 (PDE8) is a family of cAMP-specific enzymes and plays
important roles in many biological processes, including T-cell activation, testosterone production,
adrenocortical hyperplasia, and thyroid function. However, no PDE8 selective inhibitors are
available for trial treatment of human diseases. Here we report kinetic properties of the highly active
PDE8A1 catalytic domain prepared from refolding and its crystal structures in the unliganded and
3-isobutyl-1-methylxanthine (IBMX) bound forms at 1.9 and 2.1 Å resolutions, respectively. The
PDE8A1 catalytic domain has KM of 1.8 μM, Vmax of 6.1 μmol/min/mg, kcat of 4.0 s−1 for cAMP,
and KM of 1.6 mM, Vmax of 2.5 μmol/min/mg, kcat of 1.6 s−1 for cGMP, thus indicating that the
substrate specificity of PDE8 is dominated by KM. The structure of the PDE8A1 catalytic domain
has similar topology as those of other PDE families, but contains two extra helices around Asn685-
Thr710. Since this fragment is distant from the active site of the enzyme, its impact on the catalysis
is unclear. The PDE8A1 catalytic domain is insensitive to the IBMX inhibition (IC50 = 700 μM).
The unfavorable interaction of IBMX in the PDE8A1-IBMX structure suggests an important role of
Tyr748 in the inhibitor binding. Indeed, the mutation of Tyr748 to phenylalanine increases the
PDE8A1 sensitivity to several non-selective or family-selective PDE inhibitors. Thus, the structural
and mutagenesis studies provide not only insight into the enzymatic properties, but also guidelines
for design of PDE8 selective inhibitors.
Adenosine and guanosine 3′,5′-cyclic monophosphates (cAMP and cGMP) are the second
messengers that mediate the response of cells to a wide variety of hormones and
neurotransmitters and modulate many metabolic processes (1–5). Phosphodiesterases (PDEs)
are the sole enzymes hydrolyzing these cyclic nucleotides and thus play pivotal roles in the
physiological processes involving the nucleotide signaling pathway. Human genome contains
21 PDE genes that are categorized into 11 families (6–9). Alternative mRNA splicing of these
genes produces over 100 isoforms of PDE proteins. Molecules of PDEs can be divided into a
variable regulatory domain at the N-terminus and a conserved catalytic domain at the C-
terminus.
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Family selective inhibitors of PDEs have been widely studied as therapeutics for treatment of
various human diseases, including cardiotonics, vasodilators, smooth muscle relaxants,
antidepressants, antiasthmatics, and agents for improvement of learning and memory (10–
17). A well known example is the PDE5 inhibitor sildenafil (Viagra) that has been approved
for treatment of both male erectile dysfunction and pulmonary hypertension (10,18). Among
PDE inhibitors, 3-isobutyl-1-methylxanthine (IBMX) is commonly used for characterization
of enzymatic properties. IBMX is a non-selective inhibitor for most PDE families. However,
an uncategorized PDE enzyme that was purified from the rat liver homogenate is insensitive
to the IBMX inhibition (19). For its preference to cAMP over cGMP, this rat protein is probably
the first report on a fragment of PDE8.
Human genome expresses two PDE8 subfamilies (PDE8A and PDE8B), both of which are
cAMP-specific and have KM of 40–150 nM for cAMP and >100 μM for cGMP (20–23).
Isoforms of PDE8 distribute in various human tissues and are abundant in testis (24–27). PDE8
has been shown to be involved in regulation of T-cell activation (28), chemotaxis of activated
lymphocytes (29), modulation of testosterone production in Leydig cell (30), and potentiation
of biphasic insulin response to glucose (31). Recently, the H305P mutation of PDE8B1 is
reported to associate with micronodular adrenocortical hyperplasia (32) and PDE8B gene
variants are associated with thyroid-stimulating hormone levels and thyroid function (33).
Molecules of PDE8 contain a Per-ARNT-Sim (PAS) domain that is a structural motif and an
environmental protein sensor involved in many biological processes such as response to oxygen
partial pressure and redox signaling (34,35). PDE8 was reported to bind IκBβ, a regulatory
protein of transcription factor NF-κB (36), presumably in a mode that the PAS domain of PDE8
competes with NF-κB for IκBβ binding.
Although PDE8 plays important roles in the physiological processes, the molecular basis has
not been fully understood. Neither structures of any PDE8 fragments nor PDE8 selective
inhibitors have been reported. The lack of structural information on PDE8 is apparently due
to the difficulty of protein purification. While the catalytic domains of eight PDE families have
been expressed and their crystal structures have been determined (37), preparation of large
quantity of PDE8 has not been easy and the purified proteins in literature typically have low
catalytic activity (20–23). For example, the C-terminal 545 amino acid fragment of PDE8A
that was expressed in the baculovirus system had Vmax of 0.15 μmol/min/mg (20), which is
at least 10 times worse than those of other PDE families. Thus, finding an alternative and
effective way to produce large quantity of active PDE8 is essential for structural study.
Reported here are the refolding of the PDE8A1 catalytic domain, the kinetic characterization
of the refolded PDE8A1, and the crystal structures of PDE8A1 in the unliganded and IBMX-
bound forms. The structures suggest a critical role of Tyr748 in the inhibitor selectivity of
PDE8. The Y748F mutation showed increased sensitivity of the PDE8A catalytic domain to
many of non-selective and family-selective PDE inhibitors.
Experimental Procedures
Subcloning of the PDE8A catalytic domain
The Expressed Sequence Tag cDNA clone of PDE8A1 (GenBank #AF332653) was purchased
from American Type Culture Collection (category number 10325182). The cDNA fragment
for expression of the catalytic domain of PDE8A1 (residues 480–820) was amplified by PCR
and subcloned into vector pET15b. The following oligonucleotide primers that contain the
restriction sites of NdeI and XhoI were used for expression of desired genes: 5′-
GTGCCGCGCGGCAGCCATATGGCTAGCTCCCTTGATGATGTCCCAC and 3′-
GGATCCTCGAGTTACTTCATTTCGTCCAGTCCTTTC. The amplified cDNAs of
PDE8A1 and the expression vector pET15b were digested by the restriction enzymes, purified
with agarose gel, and ligated by T4 DNA ligase.
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The plasmid pET15b-PDE8A1 was transferred into E. coli strain BL21 (CodonPlus) for
overexpression. The cell containing the vector pET15b-PDE8A1 was grown in a modified
2xYT culture medium (16g trypton, 10g yeast extracts, and 5g NaCl per liter) that was
autoclaved before addition of 0.4% glucose, 100mg ampicillin, and 20mg chloramphenicol.
After the cell was grown at 37°C to A600 = 0.7, 0.1 mM isopropyl β-D-thiogalactopyranoside
(IPTG) was added to induce the overexpression at room temperature for overnight. The Y748F
mutant of PDE8A1 was constructed by the standard protocol of site-directed mutagenesis and
overexpressed in the similar conditions as the wild type PDE8A1.
Protein refolding and purification
Since the wild type PDE8A1 (480–820) and its mutant were expressed as inclusion body,
refolding was performed to obtain the soluble and active PDE8A1 proteins. About 10 grams
of frozen cell from 2 liter culture were suspended in 40 ml of the extraction buffer and past
through French Press three times at 1200 psi to homogenize it. The extraction buffer was 20
mM Tris.base, pH 7.5, 50 mM NaCl, 1 mM β-mercaptoethanol (β-ME), and 1 mM EDTA. The
homogenate was centrifuged at 15,000 rpm in a JA20 rotor for 30 min. The pellet of PDE8A
was dissolved in 10 ml buffer of 6 M guanidine, 0.1 M Tris·HCl pH 8.0 under shaking at room
temperature for 3 hours. The dissolved mixture was centrifuged at 15,000 rpm for 20 min.
The supernatant was loaded into a Ni-NTA column (φ=2.5 cm, 25 ml of QIAGEN agarose
beads). The column was washed with 100 ml buffer of 8 M urea, 0.1 M Tris·HCl pH 8.0, and
then eluted with the same buffer plus 0.5 M arginine. The eluted fractions of the PDE8A1
catalytic domain were combined and added with 10 mM β-ME and 10 mM DTT. The refolding
was initiated by addition of 30 μg/ml protein to a buffer of 0.5 M Tris·HCl pH 7.0, 20 mM
MgCl2, 20 mM MnCl2, 20 μM ZnSO4, 0.7 M arginine, 30% glycerol, 10 mM NaCl, 1 mM
KCl, and 10 mM DTT at 4°C for three days. The protein concentration was estimated by the
absorption of A280 (1.097 unit of A280 = 1 mg/ml), as calculated by program ProtParam
(38).
The refolded PDE8A1 was mixed with 15 grams of hydroxyapatite HTP GEL bead (Bio-Rad)
that was presoaked in water. After stirred at room temperature for 15 min, the suspension was
filtered with a filter paper. The bead was re-suspended in 100 ml of 20 mM Tris·HCl pH 8.0,
50 mM NaCl, 1 mM β-ME and packed into a column. The column was washed with 50 ml of
the same buffer and eluted with 100ml buffer of 20mM Tris·HCl pH 8.0, 100 mM KH2PO4,
and 1 mM β-ME. The combined fractions were dialyzed against 0.5 liter of 20 mM Tris pH
7.5, 50 mM NaCl, and 1 mM β-ME, twice, 1 hour and overnight.
To remove the His-tag, 2.5 mM CaCl2 and 1 μg/ml thrombin (Haematologic Tech. Inc.) was
added for digestion at 25°C for 1 hour. The digested PDE8A1 was loaded into a Q-sepharose
column (GE Healthcare) that was pre-equilibrated with a buffer of 50 mM NaCl, 20 mM
Tris·HCl pH 7.5, 1 mM β-ME, and 1 mM MgCl2. The column was washed with 200 ml of 20
mM Tris·HCl pH 7.5, 100 mM NaCl, 1 mM β-ME, 1 mM EDTA and then PDE8A1 was eluted
out with the same buffer but 300 mM NaCl. After concentrated to about 10 ml, the protein was
loaded into Sepharyl S-300 column (GE Healthcare) and eluted with a buffer of 20 mM
Tris·HCl pH 7.5, 50 mM NaCl, 1 mM β-ME, 1 mM MgCl2. The protein was finally
concentrated to 10 mg/ml. A typical batch of the refolding and purification yielded about 10
mg PDE8A1 from 2 liters of the refolding buffer. The protein was estimated to have purity
greater than 95%, as shown in the SDS gel.
The subcloning, expression, refolding, and purification of the PDE8A fragment (residue 205–
820) were carried out in the similar condition as those for the PDE8A catalytic domain (480–
820). The refolding buffer for the PDE8 fragment was 50 mM Tris.HCl, pH 7.0, 1.25 M urea,
1 M Arg, 40 mM MnCl2, 10 mM NaCl, 1 mM KCl, and 10 mM DTT.
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The enzymatic activities were assayed by using 3H-cAMP or 3H-cGMP as substrates, as
previously reported (39). The catalytic domain of PDE8A1 was incubated with a reaction
mixture of 20 mM Tris·HCl, pH 7.5, 4 mM MnCl2, 1 mM DTT, 3H-cAMP or 3H-cGMP
(20000–40000 cpm/assay) at 24°C for 15 min. The reaction was terminated by addition of 0.2
M ZnSO4 and 0.12 M Ba(OH)2. The reaction product 3H-AMP or 3H-GMP was precipitated
out by BaSO4 while unreacted 3H-cAMP or 3H-cGMP remained in supernatant. After
centrifugation, the radioactivity in the supernatant was measured in a liquid scintillation
counter. The turn over was controlled at hydrolysis of <30% substrate under a suitable enzyme
concentration (0.004 to 0.085 μg/ml PDE8A1). Twelve concentrations of cAMP or cGMP in
a range of 0.04 to 50 μM were used to obtain the kinetic parameters.
The enzymatic properties were analyzed by the steady state kinetics (40). The non-linear
regression of the Michealis-Menten equation, as well as Eadie-Hofstee plots were analyzed to
obtain the values of KM, Vmax, and kcat. For measurement of IC50, ten concentrations of
inhibitors were used at the substrate concentration of <1/10 KM and the suitable enzyme
concentration. All measurements were repeated three times.
Crystallization and structure determination of PDE8A
The crystal of the unliganded catalytic domain of PDE8A1 (480–820) was grown by vapor
diffusion of 10 mg/ml PDE8A1 against a well buffer of 100 mM Na cacodylate (pH 6.5), 15%
isopropanol, 30% ethylene glycol, 10% PEG3350 at 4°C. The unliganded crystal has the space
group C2221 with a = 76.3, b = 132.7, and c = 101.5 Å. The PDE8A1-IBMX crystal was grown
by the hanging drop against the same buffer for the unliganded PDE8A1, except for 8%
PEG3350. The PDE8A1-IBMX crystal has the space group P21 with cell dimensions of a =
76.3, b = 101.6, c = 76.6 Å and β = 119.9°. The diffraction data were collected on beamline
X29 in Brookhaven National Laboratory and processed by program HKL (41). The unliganded
PDE8A1 structure was solved by the molecular replacement program AMoRe (42), with
PDE4D2 as the initial model. The structure of PDE8A1-IBMX was solved by using the
unliganded PDE8A1 as the model. The atomic models were rebuilt by program O (43) against
the electron density maps that were improved by the density modification package of CCP4.
The structures were refined by CNS (Table 1, 44).
RESULTS
Kinetic properties of the refolded PDE8A1
When 4 mM MnCl2 is used as the catalytic ion, the refolded PDE8A1 catalytic domain has
KM of 1.8 ± 0.1 μM, Vmax of 6.1 ± 0.1 μmol/min/mg, and kcat of 4.0 ± 0.1 s−1 for cAMP, and
KM of 1.6 ± 0.1 mM, Vmax of 2.5 ± 0.3 μmol/min/mg, and kcat of 1.6 ± 0.2 s−1 for cGMP.
When 10 mM Mg2+ was used as the catalytic ion, the refolded PDE8A1 catalytic domain has
KM of 7.0 ± 0.1 μM, Vmax of 4.5 ± 0.1 μmol/min/mg, and kcat of 2.9 ± 0.1 s−1 for cAMP, and
KM of 1.5 ± 0.1 mM, Vmax of 0.6 ± 0.1 μmol/min/mg, and kcat of 0.4 s−1 for cGMP. The
specificity constant of (kcat/KM)cAMP/(kcat/KM)cGMP was 1680 and 2200 respectively for
the Mg2+ and Mn2+catalyses, thus confirming the early conclusion that PDE8 is cAMP-specific
(20–23). These kinetic parameters of the refolded PDE8A catalytic domain are comparable
with those of other cAMP-specific PDE families. For example, the full length PDE4D2 and
the catalytic domain of PDE7A1 have the KM values of 1.5 and 0.2 μM, kcat of 3.9 and 1.6
s−1 for cAMP, and the specificity constants (kcat/KM)cAMP/(kcat/KM)cGMP of 500 and 4000,
respectively (39). Thus, the substrate specificity of PDE4, PDE7 and PDE8A is determined by
the apparent affinity constant KM. A notable difference among these three cAMP-specific
PDEs is that the kcat of PDE8A for cGMP is about 2.5-fold lower than that for substrate cAMP,
in contrast to the comparable or even higher kcat for cGMP than those for cAMP in the cases
Wang et al. Page 4













of full length PDE4D2 and the PDE7A1 catalytic domain (39). Although the 2.5-fold difference
is marginal, kcat might have somewhat contribution to the substrate specificity of PDE8A. The
above kinetic parameters of the PDE8A catalytic domain show that the manganese is slightly
more efficient than magnesium and might thus imply that manganese is the catalytic metal ion
in cells, yet to be further studied.
An unusual observation is that KM of 1.8 μM for the catalytic domain of PDE8A1 is 12–45
fold larger than the KM values of 40–150 nM for the full length PDE8A and PDE8B, as reported
by four research groups (20–23). The KM disagreement is in contrast to our early observations
that the full length and catalytic domains of other PDE families have comparable KM values,
as shown in the cases of PDE4 (39,45), PDE7 (39,46), PDE9 (47), and PDE10 (48,49). To
study if the refolding process generates non-native conformation and thus false kinetic
behaviors, the soluble fraction of the PDE8A1 catalytic domain from the E. coli expression
was purified and assayed for its enzymatic properties. The PDE8A1 that was naturally folded
in the E. coli cell has KM of 1.5 ± 0.2 μM that is well compared with KM of 1.8 μM for the
refolded protein. In addition, the crystal structure of the refolded PDE8A1 has the similar
topology as those of other PDE families, suggesting the biologically relevant conformation.
Therefore, the different KM values between the isolated catalytic domain and the full-length
PDE8A1 likely reflect their intrinsic kinetic behaviors and the regulation of the catalytic
activity of PDE8 by the PAS domain. This argument is supported by our progress on the
preparation of the PDE8A1 fragment (residue 205–820) that contains both PAS and catalytic
domain. This fragment has KM of 0.28 ± 0.01 μM and kcat of 1.1 ± 0.01 s−1 when cAMP is
used as the substrate and 4 mM MnCl2 is the catalytic ion. The KM of 280 nM for the PDE8A
(205–820) fragment is 2–7 fold different from the values of 40–150 nM for the full length
PDE8s in literature (20–23), in comparison to 10–45 fold difference between the catalytic
domain and full-length PDE8. Therefore, the comparison of the KM values of the catalytic
domain, the fragment (205–820), and the full-length PDE8 suggests that the PAS domain
impacts the substrate binding and the catalysis, possibly via an allosteric mode. This hypothesis
is consistent with the early observation that the full-length PDE8A had an activity about 5-fold
higher than its catalytic domain and binding of the partner protein IκBβ further stimulated
about 2-fold catalytic activity (36).
Structure of the PDE8A1 catalytic domain
Almost all the residues in the PDE8A1 catalytic domain (residues 480–820) were traced
without ambiguity in both crystal structures, except for a few of the N- and C-terminal residues.
The crystallographic asymmetric units contain one molecule in the unliganded PDE8A1
crystals, but two in the PDE8A1-IBMX complex. The two molecules in PDE8A1-IBMX
apparently assemble into a dimer that is superimposable with the dimeric catalytic domain of
PDE4D2. However, it is not clear if the PDE8A1 dimer in the crystal is biologically relevant.
The catalytic domain of PDE8A1 contains 18 α-helices (Fig. 1), in comparison with 16 α-
helices in the most other PDE families (37). Structural superposition of PDE8A-IBMX over
other PDEs yielded RMS deviations of 0.94 Å for 291 comparable residues of PDE4D2-IBMX,
1.27 Å for 294 residues of PDE7A1-IBMX, and 1.37 Å for 254 residues of PDE5A1-sildenafil.
This comparison indicates the similar topology of the PDE families. The H-loop or The603-
Asn620 of PDE8A1, which is an integrated portion of the active site, is well superimposed
over the corresponding Ser208-Asn224 of PDE4D2-IBMX (Fig. 1), as well as most other PDE
families (37). However, the H-loop of PDE5A1 has been shown to exist in five different
conformations upon inhibitor binding (50,51). While the conformational changes of the H-loop
in PDE5A1 clearly suggest its role in discrimination of inhibitors, it remains puzzle how the
H-loop impacts the catalysis in the other PDE families.
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In spite of the overall structure similarity, three regions of PDE8A1 show significant
differences in the position and conformation from other PDE families. First, the N-terminal
helix H1 of PDE8A1 is not comparable with other PDE families and helix H2 is superimposable
with those of PDE4 and PDE7, but not PDE5 (Fig. 1). Thus, the PDE8 structure supported our
early proposal (37) that the core catalytic domain starts from helix H3 or the residue around
Pro512 of PDE8A1 (Pro117 of PDE4D2). Second, the PDE8A1 loop of Asn685 to Thr710
contains two α-helices and a 310-helix, and has an insert of more than 10 residues in comparison
with other PDE families (Fig. 1). This loop is distant from the active site and thus unlikely
plays an important role in the recognition of substrates and inhibitors. Third, the M-loop, which
is defined as residues of Phe749-Ser773 of PDE8A1 or Phe341-Ser364 of PDE4D2 (50,52),
shows significant conformational variation and positional difference (Fig. 1). For example, the
Cα atom of Pro764 of PDE8A1 is 3.8 Å away from the corresponding Met357 of PDE4D2 and
the Cα atom of Val763 of PDE8A1 has a distance of 7.5 Å from Pro801 of PDE5A1. Since
the M-loop is a component of the active site and is involved in interaction with inhibitors and
substrate (52), the conformational difference of the M-loop implies its role in selective
recognition of substrates and inhibitors.
While the PDE8A active site closely resembles those of cAMP-specific PDE4 and PDE7, there
are some subtle but significant differences among these structures. One notable difference is
associated with the invariant glutamine (Gln778 in PDE8A1) that has been thought to play an
important role in the inhibitor binding and the substrate recognition (37,53). Gln778 of
PDE8A1 occupies similar position and has the same conformation as the glutamines of PDE4
and PDE7. However, its side chain forms no hydrogen bonds with PDE8A residues, but two
water molecules that respectively bind to Ser745 and Trp813 (Fig. 2). In comparison, Gln369
of PDE4D2 interacts with Tyr329 and a water molecule while Gln413 in PDE7A1 forms a
hydrogen bond with Ser377 (Fig. 2). Thus, the side chain of Gln778 is more flexible than
Gln369 of PDE4D2 and Gln413 of PDE7A1, and may be capable of switching its conformation.
This observation is negative evidence for the hypothesis of “glutamine switch”, in which the
invariant glutamine was assumed to have a fixed orientation in the cAMP- or cGMP-specific
PDE families (53).
IBMX binding at the active site of PDE8A1
Since no PDE8 selective inhibitors are available at the present, dipyridamole and IBMX were
used for the structural studies to reveal inhibitor binding. Dipyridamole is a non-selective
inhibitor for most PDE families and has IC50 of 0.5–1.5 μM for PDE5 (54) and 4–9 μM for
PDE8 (20,21). The co-crystal of the PDE8A1 catalytic domain with dipyridamole showed that
dipyridamole occupies the active site of PDE8 in a similar pattern to the inhibitor binging in
other PDE families. However, the conformation of dipyridamole could not be unambiguously
determined in the crystal for unclear reason (unpublished data).
IBMX is a non-selective inhibitor for most PDE families with IC50 of 2–50 μM (55), but does
not effectively inhibit PDE8 activity at concentration up to 200 μM (20–23). This is confirmed
by the IC50 of 698 ± 29 μM for the refolded catalytic domain of PDE8A1. Nevertheless, we
hope, based on our experience in the co-crystallization of IBMX with PDE9, another IBMX-
insensitive PDE family (47), whose PDE8A-IBMX crystal revealed meaningful information
on the inhibitor binding. Indeed, the co-crystal of PDE8A1 with 2 mM IBMX showed IBMX
binding to the active site of PDE8A1 (Fig. 3). The electron density in the (2Fo-Fc) and (Fo-
Fc) maps clearly revealed the stack of the xanthine ring of IBMX against Phe781 of PDE8A1,
while the isobutyl group of IBMX has weaker electron density and is flexible (Fig. 3). In
addition, IBMX forms a hydrogen bond with each of the side chains of Tyr748 and Gln778,
and makes van der Waals’ interactions with residues Met670, Ile744, Tyr748, Phe767, Phe781,
and Phe785.
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The binding of IBMX does not significantly change the conformation of PDE8A1, as shown
by the very small RMS deviation (0.24 Å) for the structural superposition between the
unliganded PDE8A1 and PDE8A1-IBMX. This is consistent with the observations of no
significant conformational changes induced by IBMX binding in the most other PDE families,
except for PDE5 (39,47,56). In addition, two characteristic features of the IBMX binding are
conserved in the reported PDE structures: the stack against a phenylalanine and the hydrogen
bond with the invariant glutamine (Gln778 in PDE8A1). However, the orientation and position
of IBMX show some changes in the structures (Fig. 3). These differences might not be
significant, but reflect the fact that the binding pockets of PDEs are much larger than the size
of IBMX so as to allow various orientations.
Tyr748 is an important residue for selectivity of PDE8 inhibitors
The structure of the PDE8A-IBMX complex reveals that the side chain oxygen of Tyr748 forms
a hydrogen bond with N3 of IBMX, but also has a distance of 2.9 Å from the neighboring
carbon C11 (Fig. 3). Since the van der Waal force has typically 3.5 Å for an O-C interaction,
we believed that this unfavorable interaction between the tyrosine and the carbon is a factor
making IBMX bound weakly. In fact, Tyr748 is typically a phenylalanine in most PDE families,
which forms a hydrophobic environment for the inhibitor stack against Phe781. Thus, a polar
oxygen atom in this environment will weaken the hydrophobic interaction. This might be the
reason why so many PDE inhibitors bind PDE8 poorly. On the other hand, this Tyr748 could
serve as one of discriminating residues to enhance PDE8 selectivity.
To test this hypothesis, Tyr748 was mutated to phenylalanine that exists in all other PDE
families except for PDE8 and PDE9. The Y748F mutant has KM of 0.7 ± 0.1 μM, kcat of 4.3
± 0.1 s−1, and Vmax of 6.6 ± 0.2 μmol/min/mg. Thus, the catalytic efficiency of the mutant,
kcat/KM is about 2-fold better than that of the wild type PDE8A1. In addition, the Y748F mutant
of PDE8A1 has IC50 of 65.8 ± 5.0 μM for IBMX (Fig. 4), which is about 10-fold better than
the IC50 of 698 μM for the wild type PDE8A1. However, the Y748F mutant has IC50 of 4.1 ±
0.4 μM for dipyridamole, which is comparable with 6.0 ± 0.4 μM for the wild type PDE8A1.
We also measured the inhibitory potency of the following PDE inhibitors to elucidate the
impact of the mutation: non-selective inhibitors papaverine and theophylline, PDE2 inhibitor
EHNA (57), PDE3/4 dual-selective zardaverine (58), PDE4 inhibitors etazolate, rolipram, and
MK298 (59,60), PDE5 inhibitors sildenafil and zaprinast (10), and PDE7 inhibitor BRL50481
(61). As shown in Fig. 4, the most inhibitors except for EHNA demonstrated some degree of
improved inhibitory effects on the Y748F mutant. Taking these data together, we believe that
Tyr748 is likely a residue useful for development of PDE8 selective inhibitors.
DISCUSSION
Structure information has played a critical role in the discovery of drugs for treatment of human
diseases (62). PDE8 is one out of three PDE families whose crystal structures remain to be
solved (37). The unavailability of PDE8 structures is apparently due to the difficulty on
preparation of large quantity of the active enzyme. Although several research groups have
reported the expression of PDE8A and 8B in the baculovirus systems, the purified proteins
often have low catalytic activities (20–23). For example, the Vmax of 0.15 μmol/min/mg for
a 545-residue fragment of PDE8A (20) is about 40-fold less active than our PDE8A catalytic
domain (Vmax of 6.1 μmol/min/mg). A fragment of C-terminal 584 amino acids of PDE8B
that was expressed in E. coli had Vmax of 0.14 nmol/min/mg (22), which is over four
magnitudes slower than that of our refolded PDE8A catalytic domain. Therefore, the procedure
for the expression and refolding of the PDE8A catalytic domain in this paper is valuable for
not only the basic studies, but also design of PDE8 inhibitors.
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PDE8 plays important roles in many physiological processes such as modulation of testosterone
production (28–33). However, no PDE8 selective inhibitors are available for trial treatment of
any diseases. PDE8 is insensitive to many PDE inhibitors, including IBMX, rolipram,
sildenafil, and zaprinast (20–23). The crystal structure of PDE8A-IBMX reveals unique
characteristic conformation of the PDE8 active site and identified Tyr748 as a key factor
responsible for the insensitivity of PDE8 to most PDE inhibitors. The Y748F mutation makes
PDE8A more sensitive to many of PDE inhibitors (Fig. 4), thus supporting the speculation that
Tyr748 is an important residue for design of PDE8 inhibitors.
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The PDE8A1 structure. (A) Ribbon diagram of the PDE8A1 catalytic domain. The purple ball
represents the second divalent metal that needs to be identified. (B) Superposition of PDE8A1
(green ribbons) over PDE4D2 (blue ribbons) and PDE5A1-sildenafil (golden ribbons). The
comparable portions of the PDE4D2 and PDE5A1 structures were omitted. The H-loop of
PDE8A1 is similar to that of PDE4D2, but different from that of PDE5A1. (C) Dimer of
PDE8A1 catalytic domain. The H-loops (residues 604-620) form the dimer interface. (D)
Sequence alignment between PDE4D2 and PDE8A1.
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Superposition of the active site residues of the cAMP-specific PDE families. (A) Comparison
between PDE8A1 (green) and PDE4D2 (golden). Dotted lines represent the hydrogen bond.
The residues are labeled in a format of PDE8A1/PDE4D2. (B) Comparison between PDE8A1
(green) and PDE7A1 (cyan). The residues are labeled in a format of PDE8A1/PDE7A1.
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IBMX binding to PDE8A1. (A) The interaction of IBMX with the active site residues of
PDE8A1. The oxygen of the side chain of Tyr748 forms a hydrogen bond with N3 of IBMX
as marked with the dotted line, but has an energetically unfavorable distance of 2.9 Å to C11
of IBMX (the atoms are marked in Fig. 3B). (B) The superposition of IBMXs of PDE8A1
(green sticks), PDE4D2 (golden sticks), and PDE5A1 (cyan sticks). (C) The (Fo-Fc) map for
IBMX, which was contoured at 2.5 sigmas.
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Inhibition of PDE8A1. (A) Inhibition by IBMX. (B) Inhibition of the wild type PDE8A1 and
its Y748F mutant by the inhibitors of papaverine and theophylline (non-selective), EHNA
(PDE2), zardaverine (PDE3/4), etazolate, rolipram, and MK298 (PDE4), sildenafil and
zaprinast (PDE5), and BRL50481 (PDE7). The concentrations used were 100 μM for all
inhibitors and 10–20 ng/ml for PDEs. The activities of the enzymes in the absence of the
inhibitors are taken as 100%.
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Table 1
Statistics on diffraction data and structure refinement
Data collection Unliganded PDE8A PDE8A-IBMX
Space group C2221 P21
Unit cell (a, b, c, Å, β) 76.3, 132.7, 101.5 76.3, 101.6, 76.6, 119.9°
Resolution (Å) 1.9 2.1
Unique reflections 36,345 52,808
Fold of redundancy 7.4 4.0
Completeness (%) 89.0 (45.8)* 90.7 (59.6)
Average I/σ 15.2 (2.8)* 13.0 (2.9)
Rmerge 0.054 (0.26)* 0.043 (0.23)
Structure Refinement
R-factor 0.236 0.221
R-free 0.265 (10%)‡ 0.256 (10%)
Resolution (Å) 30–1.9 30–2.1
Reflections 35,445 52,075
RMS deviation for
Bond (Å) 0.005 0.006
Angle 1.1° 1.1°
Average B-factor (Å2)
 Protein 47.9 (2744)§ 51.0 (5488)
 IBMX 75.5(32)§
 Waters 40.2 (64) § 41.5 (134)
 Zn 34.9 (1) 40.2
 Mg 36.2 (1) 38.4
*
The numbers in parentheses are for the highest resolution shell.
‡
The percentage of reflections omitted for calculation of R-free.]
§
The number of atoms in the crystallographic asymmetric unit.
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